News Release

Pausing chikungunya vaccination and accelerated approval

JAMA

Peer-Reviewed Publication

JAMA Network

About The Article: This Viewpoint, by Vinay Prasad, MD, MPH, of the Center for Biologics Evaluation and Research, Food and Drug Administration, and colleagues discusses a safety communication recommending a pause in the use of live attenuated chikungunya virus vaccine. 

Corresponding Author: To contact the corresponding author, Vinay Prasad, MD, MPH, email vinayak.prasad@fda.gov.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jama.2025.9393)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.9393?guestAccessKey=7ee4662e-2b9f-49d7-a986-832e4789470b&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060525


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.